Shares of Selecta Biosciences Inc (NASDAQ:SELB) were down 5.5% during mid-day trading on Monday . The stock traded as low as $2.43 and last traded at $2.56. Approximately 517,107 shares traded hands during mid-day trading, a decline of 20% from the average daily volume of 647,324 shares. The stock had previously closed at $2.71.
Several analysts have issued reports on SELB shares. Canaccord Genuity decreased their price objective on shares of Selecta Biosciences from $25.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, March 18th. Stifel Nicolaus reissued a “buy” rating and issued a $7.00 price objective on shares of Selecta Biosciences in a research note on Friday, March 15th. Mizuho decreased their price objective on shares of Selecta Biosciences to $4.00 and set a “buy” rating for the company in a research note on Monday, February 4th. Needham & Company LLC decreased their price objective on shares of Selecta Biosciences to $12.00 and set a “buy” rating for the company in a research note on Monday, January 28th. Finally, ValuEngine downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Selecta Biosciences has a consensus rating of “Hold” and a consensus price target of $11.61.
The company has a market cap of $112.27 million, a price-to-earnings ratio of -0.83 and a beta of 1.60.
Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings results on Friday, March 15th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.10. The company had revenue of $0.90 million for the quarter. On average, research analysts predict that Selecta Biosciences Inc will post -1.47 EPS for the current year.
In related news, Director Amir Nashat purchased 1,166,666 shares of the firm’s stock in a transaction dated Friday, January 25th. The stock was purchased at an average price of $1.50 per share, with a total value of $1,749,999.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 25.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of SELB. Barclays PLC increased its holdings in Selecta Biosciences by 87.6% during the fourth quarter. Barclays PLC now owns 12,661 shares of the company’s stock valued at $34,000 after buying an additional 5,911 shares during the period. Vanguard Group Inc increased its holdings in Selecta Biosciences by 1.1% during the third quarter. Vanguard Group Inc now owns 655,771 shares of the company’s stock valued at $10,197,000 after buying an additional 6,859 shares during the period. Rhumbline Advisers increased its holdings in Selecta Biosciences by 50.3% during the fourth quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock valued at $63,000 after buying an additional 7,965 shares during the period. Two Sigma Advisers LP increased its holdings in Selecta Biosciences by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock valued at $146,000 after buying an additional 8,500 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Selecta Biosciences during the third quarter valued at approximately $196,000. 23.47% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Selecta Biosciences (SELB) Shares Down 5.5%” was first reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://macondaily.com/2019/04/17/selecta-biosciences-selb-shares-down-5-5.html.
About Selecta Biosciences (NASDAQ:SELB)
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Read More: Are sell-side analysts objective?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.